Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation

Radiation Exposure Clinical Trial

— REDEFINE  

Official title:

Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation (REDEFINE): A Prospective, Randomized Evaluation of the ControlRad System to Reduce Radiation Exposure During Cardiac Catheterization and Electrophysiology (EP) Procedures.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04404257
• Other study ID #: 2019-174
• Status: Completed
• Phase: N/A
• Start date: November 5, 2020
• Est. completion date: December 3, 2021

Study information

• Verified date: December 2022
• Source: William Beaumont Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the ControlRad system device when installed in Fluoroscopic (x-ray) machine reduces radiation dose to operators (Doctors and nurses) and to the patient who is undergoing cardiac Catheterization and electrophysiology (EP) implant procedures.

Description:

This is a Prospective, randomized (like a "flip of a coin") single center study evaluating the ControlRad system device when installed - retrofitted on existing C-arms for fluoroscopy (x-ray) will reduce radiation exposure without compromising image quality in the region of interest and overall workflow during cardiac catheterization and electrophysiology (EP) implant procedures. Enrollment will be limited to 40 cardiac catheterization, and 30 pacemaker and/or ICD procedures. All patients presenting to Beaumont Hospital Royal Oak who are scheduled for cardiac catheterization with coronary angiography and electrophysiology implant in Cath Lab 5 where device is installed will be considered for inclusion in the study. Physicians and staff (20 fellows; 35 attending physicians; and 56 Cath-lab staff,including Nurse/Anesthesia team) will be invited to participate in the study. For each procedure, 3 staff members will be study subjects: a) the primary operator, b) the secondary operator, c) the nurse/tech and or Anesthetist who circulates in the room. Different operators and staff may participate in each case depending on cath-lab scheduling. The Primary operator is the physician who usually stands nearest to the C-arm. In most cases in Beaumont this is a Cardiology Fellow in cardiac catheterization cases and Attending Physician for the EP cases. The Secondary operator is the physician who typically stands to the right of the primary operator and in most cases is the attending cardiologist or scrub assistant (nurse/technician). The Nurse or Anesthesia team typically circulates in the room and is responsible for monitoring the patient, administering medications and obtaining equipment for the procedure. Two methods will be used to measure radiation dose during the catheterization procedure. The Real-time Dosimeter Badge (RaySafe) and the Landauer Luxel Aluminium Oxide Dosimeter Badges. Cardiac Catheterization and electrophysiology implant procedures will be performed according to standard guidelines. Participants will be randomized 1:1 to either cardiac catheterization without ControlRad or cardiac catheterization with the ControlRad system. The same 1:1 randomization process will be applied to the EP patient population. Participants will be blinded to the randomization. Once procedure is done,participation also ended and the badges will be removed by the Radiation Safety Officer or research coordinator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 170
• Est. completion date: December 3, 2021
• Est. primary completion date: December 3, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• - Patient
• Scheduled to undergo left heart catheterization with angiography, and/or percutaneous coronary intervention
• Scheduled to undergo pacemaker or ICD implant
• EP device upgrade
• Able to provide written informed consent prior to the procedure
• Age =18 years
• Physicians and Staff o Able to provide consent for the study

Exclusion Criteria:

• - Patient
• Cardiogenic shock
• Reason for cath procedure is pericardiocentesis
• Subcutaneous ICDs
• Lead revisions
• Inability to provide informed consent
• Pregnant
• Physicians and Staff
• Those who are not willing to participate in the study

Related Conditions & MeSH terms

• Cardiac Catheterization
• Radiation Exposure

Intervention

Radiation:
• ControlRad System
Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
• Without ControlRad System
Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.

Locations

Country	Name	City	State
United States	Beaumont Hospital - Royal Oak	Royal Oak	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
William Beaumont Hospitals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiation Dose to Primary Operator (RaySafe), Cardiac Catheterization	Median effective radiation dose in microsievert (µSv) to the primary operator at the thyroid. This was measured using a RaySafe dosimeter to assess the radiation dose in each case.	During each cardiac catheterization, an average of 90 minutes
Primary	Radiation Dose to Primary Operator (Luxel Dosimeter), Cardiac Catheterization	Mean effective radiation dose in microsievert (µSv) to the primary operator at the thyroid. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each cardiac catheterization, an average of 90 minutes
Primary	Radiation Dose to Primary Operator, EP Procedure (Luxel)	Mean effective radiation dose in microsievert (µSv) to the primary operator at the end of each EP implant procedure. A single Luxel dosimeter was and a cumulative dose was recorded.	During each EP implant procedure, an average of 90 minutes
Primary	Radiation Dose to Primary Operator, EP Procedure (RaySafe)	Median effective radiation dose in microsievert (µSv) to the primary operator at the end of each EP implant procedure using a RaySafe dosimeter. This is measured after each case.	During each EP implant procedure, an average of 90 minutes duration
Secondary	Radiation Dose to Secondary Operator, Cardiac Catheterization (RaySafe)	Median effective radiation dose (µSv) to the secondary operator at the thyroid. This was measured using a RaySafe dosimeter to assess the radiation dose in each case.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose to Secondary Operator (Luxel Dosimeter), Cardiac Catheterization	Mean effective radiation dose in microsievert (µSv) to the secondary operator at the thyroid. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose to Nurse or Anesthetist, Cardiac Catheterization (RaySafe)	Median effective radiation dose in microsievert (µSv) to the Nurse 0r Anesthetist at the thyroid. This was measured using a RaySafe dosimeter to assess the radiation dose in each case.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose to Nurse or Anesthetist, Cardiac Catheterization (Luxel)	Mean effective radiation dose in microsievert (µSv) to the Nurse or Anesthetist at the thyroid. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose to Patient, Cardiac Catheterization	Median radiation dose-area product (DAP) to the patient at the end of each cardiac catheterization case using data from a fluoroscopy machine. DAP is defined as the absorbed dose multiplied by the area irradiated micro-gray µGy*m^2.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose in Cath Lab Room #5, Cardiac Catheterization	Mean radiation dose microsieverts (µSv) at the end of each cardiac catheterization case at a standard location on the wall of the catheterization laboratory. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each cardiac catheterization, an average of 90 minutes
Secondary	Radiation Dose to Secondary Operator, EP Procedure (RaySafe)	Mean effective radiation dose (µSv) to the secondary operator at the at the thyroid. This was measured using a RaySafe dosimeter to assess the radiation dose in each case.	During each EP implant procedure, an average of 90 minutes
Secondary	Radiation Dose to Secondary Operator, EP Procedure (Luxel)	Mean effective radiation dose (µSv) to the secondary operator at the at the thyroid. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each EP implant procedure, an average of 90 minutes
Secondary	Radiation Dose to Nurse or Anesthetist, EP Procedure (RaySafe)	Median effective radiation dose in microsievert (µSv) to the primary operator at the thyroid. This was measured using a RaySafe dosimeter to assess the radiation dose in each case.	During each EP implant procedure, an average of 90 minutes
Secondary	Radiation Dose to Nurse or Anesthetist, EP Procedure (Luxel)	Mean effective radiation dose in microsievert (µSv) to the primary operator at the thyroid. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each EP implant procedure, an average of 90 minutes
Secondary	Radiation Dose to Patient, EP Procedure	Mean radiation dose-area product (DAP) to the patient at the end of each EP implant procedure using data from a fluoroscopy machine. DAP is defined as the absorbed dose multiplied by the area irradiated (µGy*m^2)	During each EP implant procedure, an average of 30-45 minutes of active radiation
Secondary	Radiation Dose in Cath Lab Room #5, EP Procedure	Mean radiation dose (µSv) at the end of each EP implant procedure at a standard location on the wall of the catheterization laboratory. This was measured using a single Luxel dosimeter over all cases to assess the cumulative dose in the study arm.	During each EP implant procedure, an average of 90 minutes